PN-8047 / Protagonist Therap - LARVOL DELTA

Wholly-Owned Clinical and Discovery Programs:…PN-8047 (oral small molecule hepcidin functional mimetic) (ACCESS Newswire) - "IND-enabling studies are ongoing, with Phase 1 initiation anticipated in Q1 2027."

New P1 trial • Preclinical • Hematological Malignancies

Discovery Programs (ACCESS Newswire) - "Recently, Protagonist announced two new wholly owned development candidates: (i) PN-458, a novel dual GLP-GIP agonist for obesity, and (ii) PN-8047, an oral hepcidin functional mimetic complementing rusfertide, an injectable hepcidin mimetic."

New molecule • Anemia • Obesity

Discovery and Development Pipeline (ACCESS Newswire) - "The Company plans to nominate a development candidate ready for IND-enabling studies from the oral hepcidin program by year end."

Pipeline update • Hematological Malignancies